Wednesday, 13 Dec 2017

You are here

Increased Pulmonary Embolism Risk in Lupus Patients

Systemic lupus erythematosus (SLE) poses numerous vascular risks, many of which are thought to be autoantibody mediated.

A retrospective population-based analysis was done to determine the association of SLE and plumonary embolism (PE) using the National Hospital Discharge Survey data, a representative sample of hospital discharges throughout the United States.

Researchers identified PE cases for the period 2001 to 2010. Among those were identified as SLE (ICD-9 code 710.0) and PE (ICD-9 codes 415.11, 415.12, 415.13, and 415.19).

A significant association between SLE and PE, independent of sex, race, age, comorbidities, found a two-fold increase risk of PE (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.99–2.16).

Patients with a primary hypercoagulable disorder had the greatest odds of PE (OR, 15.37; 95% CI, 15.22–15.51). A higher risk was seen in those of African American (AA) race (OR, 1.08, 95% 1.08–1.09), and presence of at least 1 of the comorbidities (OR, 1.06; 95% CI, 1.06–1.06).

Females, especially AA, had an overall higher prevalence of SLE-related PE (1.67%) compared with males (1.29%). This PE-SLE association was highest for females, blacks, and age group 35 to 44 years, respectively.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Skin Remission in Dermatomyositis is Uncommon

JAMA Dermatology reports that clinical remission was relatively uncommon in dermatomyositis, despite aggressive systemic therapy, but was best in those receiving mycophenolate during a 3-year study.

Pregnancy Outcomes Worse with Myopathies

Women with the autoimmune inflammatory myopathies dermatomyositis (DM) and polymyositis (PM) are at increased risk for hypertensive disorders in pregnancy, a nationwide retrospective study found.

Health Economics of SLE

A number of presentations over the past few days have addressed the health economics of SLE.

Two Lupus Studies

In this session we were given new data on ustekinumab for SLE (abstract 6L). Ustekinumab is an IL12/23 agent already approved for use in psoriasis, psoriatic arthritis and Cohn’s disease.

EULAR/ACR SLE Classification Criteria Update

Today the draft of the new EULAR/ACR lupus classification criteria was presented at the ACR 2017.